The tumor type subgroup analysis demonstrated negative impact of elevated YAP1 on OS in patients with ESCC (HR = 1.85; 95% CI: 1.25-2.73; P = 0.002), GC (HR = 1.41,95% CI: 1.02-1.95; P = 0.037), and CRC (pooled HR = 1.75; 95% CI: 1.42-2.15; P < 0.001) (Figure 3). This evidence concerns the gene YAP1 and gastric cancer.